Related references
Note: Only part of the references are listed.Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2014)
A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck
Daniel W. Bowles et al.
INVESTIGATIONAL NEW DRUGS (2014)
Phase 2, open-label, 1:1 randomized controlled trial exploring the efficacy of EMD 1201081 in combination with cetuximab in second-line cetuximab-na⟨ve patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
A. Ruzsa et al.
INVESTIGATIONAL NEW DRUGS (2014)
Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
A. Argiris et al.
ANNALS OF ONCOLOGY (2013)
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
D. W. Bowles et al.
BRITISH JOURNAL OF CANCER (2013)
A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins
Stephen B. Keysar et al.
MOLECULAR ONCOLOGY (2013)
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
Julie E. Bauman et al.
ORAL ONCOLOGY (2013)
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
David S. Hong et al.
CLINICAL CANCER RESEARCH (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive molecular characterization of human colon and rectal cancer
Donna M. Muzny et al.
NATURE (2012)
PI3K inhibition combined with either cetuximab or docetaxel in a direct patient tumor model of HPV-positive and negative head and neck cancers
Daniel W. Bowles et al.
CANCER RESEARCH (2011)
Transient PI3K Inhibition Induces Apoptosis and Overcomes HGF-Mediated Resistance to EGFR-TKIs in EGFR Mutant Lung Cancer
Ivan S. Donev et al.
CLINICAL CANCER RESEARCH (2011)
New phosphatidylinositol 3-kinase inhibitors for cancer
Daniel W. Bowles et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2011)
PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events
Laia Agell et al.
MODERN PATHOLOGY (2011)
PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
Filip Janku et al.
MOLECULAR CANCER THERAPEUTICS (2011)
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers
Filip Janku et al.
PLOS ONE (2011)
Genomic dissection of the epidermal growth factor receptor (EGFR)/PI3K pathway reveals frequent deletion of the EGFR phosphatase PTPRS in head and neck cancers
Luc G. T. Morri et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
Nishant Agrawal et al.
SCIENCE (2011)
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Nicolas Stransky et al.
SCIENCE (2011)
Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
Lecia V. Sequist et al.
SCIENCE TRANSLATIONAL MEDICINE (2011)
Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes
Yinghui Zhang et al.
BREAST CANCER RESEARCH (2011)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Somatic Mutations in p85α Promote Tumorigenesis through Class IA PI3K Activation
Bijay S. Jaiswal et al.
CANCER CELL (2009)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
PIK3CA gene mutations and amplifications in uterine cancers, identified by methods that avoid confounding by PIK3CA pseudogene sequences
Takahito Miyake et al.
CANCER LETTERS (2008)
PIK3CA mutations and copy number gains in human lung cancers
Hiromasa Yamamoto et al.
CANCER RESEARCH (2008)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
PIKK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia
Monica Prasad Hayes et al.
CLINICAL CANCER RESEARCH (2006)
Oncogenic PI3K and its role in cancer
Y Samuels et al.
CURRENT OPINION IN ONCOLOGY (2006)
The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts
NT Ihle et al.
MOLECULAR CANCER THERAPEUTICS (2005)
Frequent mutation of the PIK3CA gene in ovarian and breast cancers
DA Levine et al.
CLINICAL CANCER RESEARCH (2005)
Synthesis and biological evaluation of synthetic viridins derived from C(20)-heteroalkylation of the steroidal PI-3-kinase inhibitor wortmannin
P Wipf et al.
ORGANIC & BIOMOLECULAR CHEMISTRY (2004)
Share Paper
